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Abstract
Background: The SYNTAX score (SXscore) has been shown to be an effective predictor of clinical outcomes 
in patients undergoing percutaneous coronary intervention (PCI).
Methods and results: The SXscore was prospectively collected in 1,397 of the 1,707 patients enrolled in the 
“all-comers” LEADERS trial (patients post-surgical revascularisation were excluded). Post hoc analysis was 
performed by stratifying clinical outcomes at two-year follow-up, according to one of three SXscore tertiles: 
SXlow ≤8 (n=464), 8<SXmid ≤16 (n=472) and SXhigh >16 (n=461). At two-year follow-up the rate of major 
adverse cardiovascular events was 18.4%, 12.0% and 9.4% in the SXhigh, SXmid, and SXlow tertile, respec-
tively (HR 1.45; CI 1.21-1.74; p<0.01). There was a significantly higher rate of cardiac death in patients in 
the highest SXscore tertile (7% SXhigh versus 2.4% SXmid versus 1.8% SXlow; HR 2.22; CI 1.5-3.27; 
p<0.001). Within the SXhigh tertile the rate of cardiac death was significantly lower in patients treated with 
the biolimus-eluting stent compared with the sirolimus-eluting stent (4.7% versus 9.6%, HR 0.48; CI 0.23-
0.99; p=0.046).
Conclusions: The SXscore when applied to an “all-comers” patient population allows for prospective risk 
stratification of patients undergoing PCI up to two years follow-up. In addition, the SXscore appears to sepa-
rate the performance of devices in high risk patient groups.
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Introduction
The SYNTAX score (SXscore) is a comprehensive angiographic 
scoring system derived from the coronary anatomy and lesion char-
acteristics1-3, which was initially designed to quantify coronary 
lesion complexity. Additional analyses have subsequently demon-
strated its ability to predict major adverse cardiac events (MACE) 
following percutaneous coronary intervention (PCI) in patients 
with multivessel coronary artery disease at follow-up ranging from 
one to five years4-6. At one-year follow-up in the ARTS-II study, 
patients with a SXscore in the highest tertile had a significantly 
higher rate of MACE compared with patients in the lower tertiles 
(HR 3.5; CI 1.7-7.4; p=0.0001), while a multivariate analysis dem-
onstrated that the SXscore independently predicted a fourfold 
increase in the risk of MACE. Furthermore, the SX score also 
showed a better discrimination ability than the AHA/ACC modified 
lesion classification (c-statistic 0.67 vs. 0.58; p<0.001).
The SXscore has not only been assessed in patients with complex 
coronary artery disease4-6 and left main disease7-8, but it has also 
been demonstrated to be a predictor of periprocedural myocardial 
infarction (MI) amongst patients undergoing elective PCI for long 
lesions and bifurcation lesions7. Most recently our group has evalu-
ated its value for risk assessment in the setting of a randomised trial 
with an “all-comers”population. In the substudy of the LEADERS 
trial (Limus Eluted from A Durable versus ERodable Stent coating), 
where the SXscore was collected prospectively in 1,397 “all-
comer” patients, we reported its prognostic value for MACE events 
at one-year follow-up8. In the current substudy we assess the value 
of the SXscore at two-year follow-up and also assess its ability to 
discriminate between the performance of two stainless steel drug-
eluting stents, one eluting biolimus from a biodegradable polymer 
and one sirolimus from a durable polymer, in the highest risk patient 
group.
Methods
STUDY POPULATION
 LEADERS was a multicentre European non-inferiority trial that 
compared the safety and efficacy of the BioMatrix™ Flex bioli-
mus-eluting stent (BES) (Biosensors, Morges, Switzerland) to the 
Cypher® sirolimus-eluting stent (SES) (Cordis, Warren, NJ, USA) 
in 1,707 “all-comers” patients. Patients over the age of 18 with 
chronic stable coronary artery disease or acute coronary syndromes 
including ST-elevation myocardial infarction were eligible if they 
had at least one lesion with ≥50% diameter stenosis and reference 
vessel diameter 2.25 to 3.5 mm. The aim was for the patient popula-
tion to reflect real world clinical practice and thus no limits were set 
on the number or complexity of the lesions stented. The only exclu-
sion criteria were: known allergy to acetylsalicylic acid, clopidog-
rel, heparin, stainless steel, sirolimus, biolimus or contrast material 
that cannot be pre-medicated; planned surgery within six months of 
percutaneous coronary intervention unless the dual antiplatelet 
therapy could be maintained throughout the perisurgical period; 
pregnancy; participation in another trial before reaching the pri-
mary endpoint; and lastly, inability to give informed consent. The 
study complied with the Declaration of Helsinki and was approved 
by all institutional ethics committees. All patients provided written, 
informed consent for participation in the trial.
SYNTAX SCORE AND ANGIOGRAPHIC ANALYSIS
From the baseline diagnostic angiogram, each coronary lesion pro-
ducing ≥50% diameter stenosis in vessels ≥1.5 mm was scored 
separately and added together to provide the overall SXscore, 
which was calculated prospectively using the SXscore algorithm 
that is described in full elsewhere1-3. All angiographic variables 
pertinent to SXscore calculation were computed by independent 
core laboratory analysts (Cardialysis B.V., Rotterdam, The 
Netherlands).
The initial description of the SXscore did not report a methodol-
ogy for calculating the SXscore in patients presenting with an 
ST-elevation MI or those with in-stent restenosis lesions. Nevertheless, 
in the present study core lab analysts were blinded to all clinical data 
and therefore patients presenting with an ST-elevation MI had their 
occluded infarct-related artery scored as an occlusion of unknown 
duration in the same manner as any chronically occluded artery; 
a methodology that has subsequently been confirmed as the most 
appropriate method of SXscoring these patients9. No validation of 
calculating the SXscore has been performed in patients with in-stent 
restenotic lesions, and they were therefore scored in the same manner 
as if the lesion was a de novo lesion.
LIMITATIONS
The methods employed for scoring in-stent restenosed arteries has 
not been validated, and does not take into account some of the 
potentially different lesion characteristics of an acutely occluded 
artery or a restenosed lesion compared to a de novo lesion. How-
ever, these methods do allow the weighted score of the anatomical 
segment to be recorded, and do allow some of the lesion character-
istics to be scored (e.g., lesion length, tortuosity, calcification, etc.). 
RANDOMISATION AND PROCEDURES
Randomisation was done centrally after diagnostic cardiac cathe-
terisation and before percutaneous coronary intervention (PCI) by 
use of a telephone allocation service (Limburgia Telefonische 
Antwoord Service BV, Rotterdam, The Netherlands). The alloca-
tion sequence was computer-generated, stratified according to 
centre, and blocked with block sizes of 8 and 16, which varied 
randomly. Patients were randomly allocated on a 1:1 basis to 
treatment with BES or SES, and to active angiographic follow-up 
at nine months or clinical follow-up only on a 1:3 basis with a fac-
torial design.
BES were available in diameters of 2.25, 2.5, 3.0 and 3.5 mm and 
in lengths of 8, 11, 14, 18, 24 and 28 mm. SES were available in 
diameters of 2.25, 2.5, 2.75, 3.0 and 3.5 mm and in lengths of 8, 13, 
18, 23, 28 and 33 mm. Balloon angioplasty and stent implantation 
were performed according to standard technique and direct stenting 
was allowed. No mixture of drug-eluting stents was permitted 
within a given patient, unless the operator was unable to insert the 
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study stent, in which case crossover to another device of the opera-
tor’s choice was possible. Before or at the time of the procedure, 
patients were given at least 75 mg of acetylsalicylic acid, 300-
600 mg loading dose of clopidogrel, and unfractionated heparin at 
a dose at least 5,000 I or 70-100 IU/kg. After the procedure, all 
patients were advised to take aspirin indefinitely and clopidogrel 
for at least 12 months. In case of inter-current revascularisation pro-
cedures requiring stent implantation, treating cardiologists were 
encouraged to use the study stent. For other details please refer to 
the primary endpoint manuscript10.
FOLLOW-UP
Adverse events were assessed in the hospital and at 1, 6, 9, 12 and 
24 months. One in four patients was asked to return for angio-
graphic follow-up at nine months.
STUDY ENDPOINTS
Definitions of all endpoints are provided elsewhere10. The primary 
endpoint of this substudy was MACE, defined as the composite of 
cardiac death, MI, and clinically-indicated target vessel revasculari-
sation (TVR) within 24 months. Secondary endpoints were any tar-
get lesion revascularisation (TLR) (both clinically and non-clinically 
indicated), which was defined as repeat revascularisation due to a 
stenosis within the stent or within a 5 mm border proximal or distal 
to the stent, any TVR, cardiac death, death from any cause, myocar-
dial infarction, stent thrombosis (defined according to the Aca-
demic Research Consortium11), device success (defined as 
achievement of a final residual diameter stenosis of less than 50% 
during the initial procedure), and lesion success (achievement of 
less than 50% stenosis with any approach for PCI).
The pre-specified principal outcome of the angiographic sub-
study was in-stent percent diameter stenosis. Secondary angio-
graphic outcomes were in-segment percent diameter stenosis, 
minimal lumen diameter, late lumen loss, and binary restenosis. 
Angiographic measurements were obtained within the stented seg-
ment (in-stent) and over the entire segment consisting of the stent 
and 5 mm proximal and distal margins (in segment). Percent diam-
eter stenosis was defined as ([reference vessel diameter-minimal 
luminal diameter]/reference vessel diameter) × 100%; late lumen 
loss was defined as the difference between minimal lumen diameter 
after the procedure and minimal lumen diameter at follow-up; and 
binary restenosis was defined as a percentage diameter stenosis of 
50% or greater in the target lesion.
A blinded independent clinical events committee adjudicated all 
endpoints, and independent study monitors (D-Target, Montagny-
pres-Yverdon, Switzerland) verified all case reports from data on-
site. Data were store in a database (KIKA Medical, Paris, France), 
which was maintained by a contract research organisation 
(Cardialysis, Rotterdam, The Netherlands) in collaboration with an 
academic clinical trials unit (CTU Bern, Bern University Hospital, 
Bern, Switzerland). The operators were by necessity aware of the 
assigned study stent during PCI and angiographic follow-up, but 
patients and staff involved in follow-up assessment were blinded to 
the allocated stent type. Angiographic films were centrally assessed 
at one angiographic core laboratory (Cardialysis, Rotterdam, The 
Netherlands) with assessors unaware of the allocated stent.
STATISTICAL ANALYSIS
A stratified post hoc analysis of clinical and angiographic out-
comes, which was specified after completion of patient recruitment, 
was performed according to the tertiles of SYNTAX score. The 
methodology used was similar to that used previously by Valgimigli 
et al in the ARTS-II study, and by Serruys et al in the SYNTAX 
trial4,5, as well as by Wykrzykowska et al8. Dedicated software and 
visual coronary angiography served to determine the SXscore as 
previously described1,2. All randomised patients without prior surgi-
cal revascularisation, in whom the SXscore was collected prospec-
tively (1,397/1,707), were included in the analysis of primary and 
secondary clinical endpoints according to tertiles of SYNTAX 
score. Analyses of the angiographic substudy were restricted to 
lesions from patients who attended follow-up angiography. Angio-
graphic outcomes were analysed using SAS v8 Proc Mixed for con-
tinuous and Proc Genmod for binominal outcomes,       taking into 
account the within-patient correlation structure of these data. We 
used a Cox proportional hazards model to compare clinical out-
comes between the groups. All analyses were performed using SAS 
8.02 (SAS Institute Inc, Cary, NC, USA) by a dedicated statistician. 
All p-values and CIs were two-sided.
Results
SYNTAX SCORE AND BASELINE CHARACTERISTICS
The SXscore was collected prospectively in 1,397 of the 1,707 
patients (81.8%) enrolled in the LEADERS trial. The predominant 
reason for not calculating the score was a history of prior surgical 
revascularisation. In this post hoc analysis, the 1,397 patients were 
divided according to their SXscore into tertiles defined as: SXlow 
≤8 (n=467), 8<SXmid ≤16 (n=472) and SXhigh >16 (n=461).
The baseline clinical and angiographic data according to the 
three SXscore tertiles has been previously reported and is included 
in Tables 1 and 28. Briefly, the SXscore ranged from 1 to 49, with 
a mean ±SD of 13.5±8.7, and a median of 12 (inter-quartile range 
of 12; 7 to 19). Overall, at one year patients in the highest SXscore 
tertile had a significantly higher rate of death, TVR, MACE and a 
trend for high rates of MI.
TWO-YEAR CLINICAL OUTCOMES FOR THE OVERALL STUDY 
POPULATION
At two-year follow-up the MACE rate was 18.4% in the SXhigh 
tertile, 12.0% in the SXmid and 9.4% in the SXlow tertile (HR 
1.45; CI 1.21-1.74; p<0.01) (Figure 1A). In addition, there was a 
significantly higher rate of cardiac death in patients in the highest 
SXscore tertile (SXhigh 7.0% versus SXmid 2.4% versus SXlow 
1.8%; HR 2.22; CI 1.5-3.27; p<0.001) (Figure 1B). Myocardial 
infarction was higher in patients in the SXhigh and SXmid groups 
(6.2%) than in patients with SXlow group (4.3%), but this differ-
ence was not statistically significant (HR 1.18; CI 0.89-1.56; 
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p=0.24) (Figure 1 E). Clinically driven TVR was 10.2% in the 
SXhigh group versus 6.9% and 5.2% in the SXmid and SXlow 
groups (HR 1.45; CI 1.14-1.85; p=0.003). (Figure 1 C)
Secondary endpoint of clinically driven TLR was 10.6% in the 
SXhigh group versus 7.5% and 5.7% in the SXmid and SXlow groups, 
respectively (HR 1.38; CI 1.09-1.76; p=0.007) (Figure 1 D).
DIFFERENTIAL PERFORMANCE OF THE BES AND SES IN 
THE HIGH SYNTAX SCORE GROUP
The analysis of outcomes in patients treated with BES versus SES 
was performed in all three tertiles of the SXscore, however, differ-
ences between the two devices were only apparent in the SXhigh 
group (highest risk) and are reported here (Figure 2). Baseline clini-
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Figure 1. SYNTAX score in leaders. A) MACE rate; B) Cardiac death rate; C) Clinically indicated TVR rate; D) TLR rate; E) MI rate.
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cal and angiographic characteristics, and angiographic outcomes 
for the SXhigh group treated with BES versus SES are reported in 
Tables 3-5. There were no significant differences between BES- 
and SES-treated group in terms of baseline characteristics and there 
was an equal distribution of the two devices between the SXscore 
tertiles (Table 2).
Overall MACE rate was 15.3% in the SXhigh group treated with 
BES versus 21.8% in the SXhigh group treated with SES (HR 0.68; 
Table 1. Baseline clinical characteristics based on SYNTAX tertiles.
Baseline clinical 
variables, (%)
SX score  
<8 
N=464
SX score 
8-16 
N=472
SX score 
>16 
N=461
p-value on 
trend 
(2-sided )
Age >65 210  (45) 224  (47) 239 (52) 0.045
Male 346 (75) 344 (73) 340 (74) 0.78
Diabetes 93 (20) 117 (25) 111 (24) 0.14
Current smoking 134 (29) 121 (26) 126 (27) 0.60
Hypertension 353 (76) 353 (75) 324 (70) 0.045
Hypercholesterolaemia 314 (68) 314 (67) 285 (62) 0.06
Family history 201 (43) 188 (40) 168 (36) 0.033
Renal insufficiency 17 (4) 21 (5) 28 (6) 0.09
Previous MI 132 (28) 145 (31) 137 (30) 0.67
Previous PCI 179 (39) 165 (35) 147 (32) 0.033
Clinical presentation
Stable 146 (31) 154  (33) 108  (23) 0.008
Unstable 127 (27) 89 (19) 88 (19) 0.002
STEMI 46 (10) 90 (19) 128 (28) <0.001
Table 2. Baseline angiographic characteristics by SYNTAX tertiles.
Angiographic variable
SX score 
<8
SX score 
8-16
SX score 
>16
p-value
No. of diseased lesions per patient  
(based on SYNTAX application)
1.47 (0.66) 2.37 (1.00) 3.45 (1.44) <0.001
No. of treated lesions per patient  
(as defined by corelab)
1.20 (0.46) 1.47 (0.70) 1.69 (0.86) <0.001
Coronary artery treated
LAD 162 (35%) 242 (51%) 296 (64%) <0.001
LCX 140 (30%) 144 (31%) 164 (36%) 0.079
RCA 216 (47%) 209 (44%) 174 (38%) 0.007
2-vessel disease 49 (11%) 102 (22%) 138 (30%) <0.001
3-vessel disease 3 (1%) 13 (3 %) 23 (5%) <0.001
Stent type
Biolimus 229 (49%) 235 (50%) 239 (52%) NS
Sirolimus 235 (51%) 237 (50%) 222 (48%) NS
Number of implanted stents 1.47 (0.66) 1.90 (1.12) 2.33 (1.39) <0.001
Total stent length/patient (mm) 25.9 (16.5) 34.2 (21.7) 42.9 (26.2) <0.001
Chronic total occlusion 6 (1%) 10 (2%) 19 (4%) 0.006
Moderate to severe calcification 23 (5%) 96 (20%) 184 (40%) <0.001
Bifurcation lesion 57 (12%) 161 (34%) 184 (40%) <0.001
Use of 2b3a 80 (17%) 113 (24%) 154 (33%) <0.001
CI 0.44-1.04; p=0.08) (Figure 2A). Within the SXhigh tertile the 
rate of cardiac death was significantly lower in patients treated with 
BES (4.7%) than SES (9.6%) (HR 0.48; CI 0.23-0.99; p=0.046) 
(Figure 2 B). Interaction between SXscore tertile and stent type in a 
five-covariate model was statistically significant (HR=0.37; 
p=0.036) and in a three-covariate model showed a trend towards 
statistical significance (HR 0.5; p=0.08), which may imply that the 
effect is due to chance alone given the low patient numbers ana-
lysed. TLR and TVR rates also tended to be lower in the BES-
treated group (8.7% versus 12.7% for clinically driven TVR; HR 
0.65; CI 0.36-1.15; p=0.14; 8.3% versus 13.1% for TLR; HR 0.59; 
CI 0.33-1.05; p=0.07) (Figure 2 C and D). The rate of MI remained 
numerically higher with BES, which was driven by early events 
occurring within the first nine months of stent implantation. Of note, 
there were no additional MIs with BES between one- and two-year 
follow-up compared with an increase in MI rate from 4.6% to 5.1% 
between year one and two in the SES-treated group (Figure 2 E).
STENT THROMBOSIS RATES FOR THE HIGH SYNTAX SCORE 
GROUP AT TWO-YEAR FOLLOW-UP
Definite stent thrombosis rates were 2.6% in the BES-treated 
group and 5.1% in the SES-treated group within the SXhigh ter-
tile at two years (HR 0.5; CI 0.18-1.34; p=0.17) (Figure 3 A). 
Notably, there were no further definite stent thrombosis events in 
the BES-treated group between year one and two. In contrast, the 
definite stent thrombosis rate increased from 4.6% to 5.1% in the 
SES-treated group. Combined definite and probable stent throm-
bosis rates were 3.8% (n=9) for BES and 5.5% (n=12) for SES 
(HR 0.68; CI 0.29-1.62; p=0.39) (Figure 3 B and Figure 3 B’). 
Most of the events occurred early after stent implantation (Figure 
3B’). Possible stent thrombosis was 2.6% in the BES group versus 
4.8% in the SES group (HR 0.54; CI 0.2-1.49; p=0.23) (Fig-
ure 3 C). The rate of overall stent thrombosis in the SXhigh group 
was 6.0% (n=14) in patients treated with BES and 9.8% (n=21) in 
patients treated with SES (HR 0.6; CI 0.31-1.18; p=0.14) (Fig-
ure 3 D). The increase in stent thrombosis in SXhigh group 
between year one and two was 0.9% for patients treated with BES 
and 2.4% for patients treated with SES. When curves for cardiac 
death rate and overall stent thrombosis rate were superimposed, 
most of the cardiac death events could be accounted for by stent 
thrombosis events, implying that reduced thrombosis rate may be 
the mechanism responsible for the reduced cardiac mortality rate 
in patients treated with BES in the SXhigh tertile (Figure 3 E), 
although this remains speculative.
Discussion
The SXscore has previously been applied in both the SYNTAX trial 
and the ARTS-II study, both of which demonstrated the good predictive 
value of the SXscore in patients with multivessel disease, with those 
patients in the highest tertile group having significantly more MACE 
events during short-4,5 and long-term follow-up6. More recently we 
reported the utility of the SXscore as a predictor of MACE, including 
cardiac death, in an ‘all-comers’ population of the LEADERS trial at 
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Figure 2. Two-year clinical outcomes for patients with the high SYNTAX score (>16) treated with BES versus SES.
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one-year follow-up8. Patients with a high SXscore (SXscore>16) had a 
50% higher chance of a MACE event, and a 154% higher chance of 
cardiac death at one year. A high SX score conferred a 2.5-fold increase 
in cardiac death, which remained true even after adjustment for other 
risk factors for cardiac death such as diabetes, presentation with acute 
coronary syndrome, beta-blocker use and stent type. Here we report 
that the predictive value of SXscore remains robust at two-year follow-
up in this “all-comers” patient population.
The major finding of our study is that the SXscore may be an 
appropriate tool to stratify risk in all patients undergoing PCI out to 
medium-term follow-up. The second finding in this study is that 
SXscore appears to be able to discriminate between the perfor-
mances of different types of stents in high risk lesions. Patients with 
high SXscores treated with BES had a lower risk of MACE and car-
diac death at two-year follow-up compared with patients treated 
with SES. These results suggest that the SXscore may be a useful 
tool in future clinical trials of new stent devices, particularly those 
with an “all-comers” design.
The mechanism of this superior performance with BES compared 
to SES in the high risk lesions and patient populations remains to be 
established. It remains a possibility that the differences in outcome 
may be a play of chance considering the small number of patients in 
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Figure 3. Stent thrombosis at 2-year follow-up.
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the high SXscore tertile. While the interaction between stent type and 
SYNTAX score tertile is significant in the five-variable model, it 
only shows trend toward significance in the three-variable model. 
Furthermore the effect is non-uniform across the SYNTAX tertiles, 
as BES reduces risk in the high SYNTAX score population but 
appears to have comparable risk in the middle tertile and higher risk 
in the low SYNTAX score tertile. These effects may be due to under-
powering of the subgroup analysis. Speculatively, the stent thrombo-
sis data presented here, and the previously reported optical coherence 
tomography data12 (Figure 4), suggest that the reduction in mortality 
rate by treatment with BES may be explained by the better stent strut 
coverage, and less acquired malapposition seen in patients treated 
with BES compared with SES.
Overall the superior performance of BES compared to SES in 
these complex patients provides additional data to support the con-
cepts behind the newer generation drug-eluting stents, which were 
primarily designed to improve overall safety following the con-
cerns raised with first generation devices13. In comparison to the 
permanent polymer present on SES, which remains exposed to the 
coronary artery environment long after its useful function has been 
served, the polymer on the biolimus-eluting stent completely biode-
grades within 6-9 months of stent implantation, leaving a bare 
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n     
stainless steel stent. Although the lower stent thrombosis rates, and 
cardiac mortality observed in this study are encouraging, addi-
tional, larger-powered studies are required before definitive conclu-
sions can be reached.
Limitations
This analysis is subject to inherent limitations of all subgroup 
analyses such as statistical under-powering. The interaction of the 
stent and SYNTAX score effects is only statistically significantly 
in the five-variable model and appears to be heterogeneous 
throughout the three SYNTAX score tertiles. As such it can only 
be viewed as hypothesis-generating. Patients with prior coronary 
artery bypass surgery have not been included in the current analy-
sis as the SXscore algorithm is only currently available for 
patients with de novo disease. Modifications to the SXscore that 
will allow for risk stratification in patients post-CABG are being 
Table 5. Angiographic follow-up results of SXhigh patients.
Biolimus stent 
75 lesions
Sirolimus stent 
73 lesions
p
MLD
in-stent (mm) 2.19±0.61 2.12±0.68 0.53*
in-segment (mm) 1.97±0.57 1.88±0.63 0.34*
Diameter stenosis
in-stent (%) 21.7±16.7 22.4±19.2 0.82*
in-segment (%) 27.8±16.1 29.2±17.3 0.60*
Late lumen loss
in-stent (mm) 0.08±0.36 0.13±0.50 0.51*
in-segment (mm) 0.08±0.35 0.09±0.45 0.84*
Binary restenosis
in-stent (%) 4±5.3 4±5.5 1.00**
in-segment (%) 5±6.7 4±5.5 1.00**
*two sided t-test, equal variance; ** Fisher exact test used for p-value, 
95% CI; Based on t-test
Table 3. Baseline clinical SXhigh patient characteristics.
BioMatrix Flex™ 
239 patients
Cypher® Select™ 
222 patients
Age in years 5.8 (106.3) 65.2 (11.3) p=0.59
Male gender 175 (73.2%) 165 (74.3%) p=0.83
Arterial hypertension 166 (69.5%) 158 (72.2%) p=0.76
Diabetes mellitus 65 (27.2%) 46 (20.7%) p=0.13
insulin-dependent 28 (11.7%) 21 (9.5%) p=0.45
Hypercholesterolaemia 139 (58.2%) 146 (65.8%) p=0.10
Family history 86 (36.0%) 82 (36.9%) p=0.85
Smoking 61 (25.5%) 65 (29.3%) p=0.40
Previous MI 70 (29.3%) 67 (30.2%) p=0.84
Previous PCI 78 (32.6%) 69 (31.1%) p=0.76
with drug-eluting stent 24 (10%) 22 (9.9%) p=1.00
Previous CABG 4 (1.7%) 4 (1.8%) p=1.00
Chronic stable angina 52 (21.8%) 56 (25.2%) p=0.38
Table 4. Baseline SXhigh clinical and angiographic patient 
characteristics.
BioMatrix Flex™ 
239 patients
Cypher® Select™
222 patients
Acute coronary syndrome 158 (66.1%) 155 (69.8%) p=0.43
Unstable angina 48 (20.1%) 40 (18%) p=0.64
Non-ST-elevation MI 50 (20.9%) 47 (21.2%) p=1.00
ST-elevation MI 60 (25.1%) 68 (30.6%) p=0.21
Left ventricular ejection fraction 54.5% (10.3) 52.8% (11.9) p=0.21
Number of eCRF lesions treated  
with stent per patient*
1.89 (0.99) 2.00 (1.13) p=0.25
Number of study stent implanted  
per patient
2.27 (1.34) 2.38 (1.45)p=0.39
Diameter of study stent (mm) 2.94 (0.42) 2.95 (0.42) p=0.70
*eCRF: electronic case report form
Figure 4. OCT images of strut coverage (from Barlis et al12 with kind permission from Oxford University Press).
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developed by our group. While the SXscore was collected pro-
spectively, the analysis of outcomes was performed post hoc. In 
addition, while SXscore has not been validated in patients post-
PCI and with acute myocardial infarction, these patients have 
been included in this analysis. The multivariate analysis was not 
performed utilising multiple covariates as the number of adverse 
events was too low to incorporate more than five, and in some 
instances three, variables.
Conclusion
This study demonstrates that the prognostic value of the SYNTAX 
score is valid for all patients with de novo coronary artery disease 
undergoing percutaneous revascularisation out to two-years of fol-
low-up. A potential new application of the SYNTAX score in future 
clinical trials is its ability to discriminate between the performance 
of novel versus first-generation stents in high risk lesions. The anal-
ysis is limited, however, due to under-powering and must be con-
sidered only as hypothesis-generating.
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